Advertisement

Topics

Acorda Takes Another Hit, Reports Patient Deaths in Parkinson’s Study

08:06 EST 15 Nov 2017 | Xconomy

Acorda Therapeutics’ rebuilding plan just suffered another setback, leaving the fate of one of the experimental Parkinson’s disease drugs that is closest to market unclear. Ardsley, NY-based Acorda (NASDAQ: ACOR) said Wednesday morning that it has seen troubling safety problems in a Phase 3 trial of its experimental Parkinson’s disease drug tozadenant. Acorda reported cases […]

Original Article: Acorda Takes Another Hit, Reports Patient Deaths in Parkinson’s Study

NEXT ARTICLE

More From BioPortfolio on "Acorda Takes Another Hit, Reports Patient Deaths in Parkinson’s Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...